Development and Evaluation of Novel Aptamers Specific for Human PD1 Using Hybrid Systematic Evolution of Ligands by Exponential Enrichment Approach

An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal

(2017) Mostafa Khedri et al.   JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION

An aptamer for recognizing the transmembrane protein PDL-1 (programmed death-ligand 1), and its application to fluorometric single cell detection of human ovarian carcinoma cells

(2017) Rezvan Yazdian-Robati et al.   MICROCHIMICA ACTA

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

(2017) Shuguang Tan et al.   Protein & Cell

Co-stimulate or Co-inhibit Regulatory T Cells, Which Side to Go?

(2016) Weifeng Liu et al.   IMMUNOLOGICAL INVESTIGATIONS

TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy

(2016) Xin-guang Liu et al.   IMMUNOLOGICAL INVESTIGATIONS

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

(2016) Junzo Hamanishi et al.   International Journal of Clinical Oncology

Cancer immunotherapy via nucleic acid aptamers

(2015) Mostafa Khedri et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers

(2015) Aaron Prodeus et al.   Molecular Therapy-Nucleic Acids

Aptamer-targeted Antigen Delivery

(2014) Brian C Wengerter et al.   MOLECULAR THERAPY

Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer

(2013) Parag Parekh et al.   BIOMATERIALS

Use of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors

(2013) E. Gilboa et al.   CLINICAL CANCER RESEARCH

At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy

(2013) Margaret K. Callahan et al.   JOURNAL OF LEUKOCYTE BIOLOGY

CD28 Aptamers as Powerful Immune Response Modulators

(2013) Fernando Pastor et al.   Molecular Therapy-Nucleic Acids

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

Isolation and Optimization of Murine IL-10 Receptor Blocking Oligonucleotide Aptamers Using High-throughput Sequencing

(2012) Alexey Berezhnoy et al.   MOLECULAR THERAPY

Probing the SELEX Process with Next-Generation Sequencing

(2011) Tatjana Schütze et al.   PLoS One

PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1

(2010) M. Ghiotto et al.   INTERNATIONAL IMMUNOLOGY

Development of DNA aptamers using Cell-SELEX

(2010) Kwame Sefah et al.   Nature Protocols

Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures

(2010) Günter Mayer et al.   Nature Protocols

Targeting cancer cells with nucleic acid aptamers

(2010) Laura Cerchia et al.   TRENDS IN BIOTECHNOLOGY

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis

(2008) Yingmiao Liu et al.   BIOLOGICAL CHEMISTRY

Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice

(2008) James O. McNamara et al.   JOURNAL OF CLINICAL INVESTIGATION